Bromo adjacent homology domain-containing protein 1 (BAHD1)

Bromo adjacent homology domain-containing protein 1 (BAHD1) is a vertebrate-specific nuclear chromatin regulator that promotes heterochromatin formation and transcriptional repression by acting as an effector in epigenetic silencing complexes[1][2][3][4][5]. It contains a C-terminal bromo adjacent homology (BAH) domain and an N-terminal proline-rich region, facilitating interaction with chromatin mark reader proteins (such as HP1, MBD1), histone deacetylases (HDAC1/2/5), and histone methyltransferases (KMT1E/G9a) to organize large-scale heterochromatin domains and direct repressive histone marks (e.g., H3K27me3)[1][2][3][4][6]. BAHD1 is directly targeted by certain pathogen proteins (e.g., LntA from Listeria monocytogenes), highlighting a role in modulating the innate immune response[1]. Functional studies show BAHD1 represses genes involved in cell proliferation, survival, metabolism, and immune signaling, and disruptions in BAHD1 function have been linked to developmental abnormalities, metabolic disorders, inflammation, and cancer progression[1][4]. BAHD1 does not directly correspond to a common therapeutic target class like receptor or enzyme; instead, it is a chromatin-associated factor and transcriptional repressor acting within multiprotein complexes[4][5]. Currently, there are no known drugs specifically targeting BAHD1, nor is it used as a biomarker or noted for safety concerns.

Other names

KIAA0945BAH domain-containing protein 1bromo adjacent homology domain-containing 1 protein